Fibrates and statins and glitazones (oh my!)
ACRIA Update, Spring 2002 – Vol. 11, No. 2
It’s hard to say what’s more frustrating – the fact that we still don’t know what causes lipodystrophy, or the fact that we still don’t know how best to treat it.
Even if researchers eventually conclude that specific antiretrovirals are responsible for the more dangerous manifestations of this syndrome – most notably increases in lipid levels and insulin resistance – it’s not clear what this pronouncement will actually mean for people with HIV.
For example, it’s not as if any of us can afford to avoid the protease inhibitors.
They remain one of the most powerful virus-clobbering tools we have, and many of us wouldn’t get very far without them.
Full text at: